1-9 of 9
Keith Flaherty
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

Shengnan Yu, Shiyou Wei, Milan Savani, Xiang Lin, Kuang Du, Ilgen Mender, Silvia Siteni, Themistoklis Vasilopoulos, Zachary J. Reitman, Yin Ku, Di Wu, Hao Liu, Meng Tian, Yaohui Chen, Marilyne Labrie, Casey M. Charbonneau, Eric Sugarman, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Wen Jiang, Roger E. McLendon, Edward Pan, Mustafa Khasraw, Kyle M. Walsh, Yiling Lu, Meenhard Herlyn, Gordon Mills, Utz Herbig, Zhi Wei, Stephen T. Keir, Keith Flaherty, Lunxu Liu, Kongming Wu, Jerry W. Shay, Kalil Abdullah, Gao Zhang, David M. Ashley
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6800–6814.
https://doi.org/10.1158/1078-0432.CCR-21-0374
Published: 15 December 2021
View article titled, A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas
Open the PDF for A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas in another window
Includes: Supplementary data
Journal Articles

Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

Charles Marusak, Varsha Thakur, Yuan Li, Juliano T. Freitas, Patrick M. Zmina, Vijay S. Thakur, Mayland Chang, Ming Gao, Jiufeng Tan, Min Xiao, Yiling Lu, Gordon B. Mills, Keith Flaherty, Dennie T. Frederick, Benchun Miao, Ryan J. Sullivan, Tabea Moll, Genevieve M. Boland, Meenhard Herlyn, Gao Zhang, Barbara Bedogni
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 6039–6050.
https://doi.org/10.1158/1078-0432.CCR-19-2773
Published: 13 November 2020
View article titled, Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Open the PDF for Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma in another window
Includes: Supplementary data
Journal Articles

Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma

Wenxin Xu, Maneka Puligandla, Judith Manola, Andrea J. Bullock, Daniel Tamasauskas, David F. McDermott, Michael B. Atkins, Naomi B. Haas, Keith Flaherty, Robert G. Uzzo, Janice P. Dutcher, Robert S. DiPaola, Rupal S. Bhatt
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6098–6106.
https://doi.org/10.1158/1078-0432.CCR-19-0818
Published: 15 October 2019
View article titled, Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Open the PDF for Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo

Heike Niessner, Jennifer Schmitz, Ghazaleh Tabatabai, Andreas M. Schmid, Carsten Calaminus, Tobias Sinnberg, Benjamin Weide, Thomas K. Eigentler, Claus Garbe, Birgit Schittek, Leticia Quintanilla-Fend, Benjamin Bender, Marion Mai, Christian Praetorius, Stefan Beissert, Gabriele Schackert, Michael H. Muders, Matthias Meinhardt, Gustavo B. Baretton, Reinhard Dummer, Keith Flaherty, Bernd J. Pichler, Dagmar Kulms, Dana Westphal, Friedegund Meier
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5818–5828.
https://doi.org/10.1158/1078-0432.CCR-16-0064
Published: 30 November 2016
View article titled, PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

Ademi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, Michelle Casey, Georgina V. Long, Dirk Schadendorf, Keith Flaherty, Richard Kefford, Axel Hauschild, Patrick Hwu, Patricia Haney, Anne O'Hagan, Jennifer Carver, Vicki Goodman, Jeffrey Legos, Anne-Marie Martin
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (3): 567–574.
https://doi.org/10.1158/1078-0432.CCR-15-0321
Published: 31 January 2016
View article titled, Correlation of <em>BRAF</em> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Open the PDF for Correlation of <em>BRAF</em> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Abstract PR06: A co-clinical assessment of patterns of BRAF inhibitor resistance

Lawrence N. Kwong, Genevieve Boland, Dennie T. Frederick, Timothy Helms, John P. Miller, Shan Jiang, Zachary A. Cooper, Alexei Protopopov, Gordon B. Mills, Keith Flaherty, Jennifer A. Wargo, Lynda Chin
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): PR06.
https://doi.org/10.1158/1557-3265.PMS14-PR06
Published: 13 February 2015
View article titled, Abstract PR06: A co-clinical assessment of patterns of BRAF inhibitor resistance
Journal Articles

Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors

Cory Johannessen, David Konieczkowski, Omar Abudayyeh, Jong Wook Kim, Zachary Cooper, Adriano Piris, Dennie Frederick, Michal Barzily-Rokni, Ravid Straussman, Rizwan Haq, David Fisher, Jill Mesirov, William Hahn, Keith Flaherty, Jennifer Wargo, Pablo Tamayo, Levi Garraway
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): PR04.
https://doi.org/10.1158/1557-3265.PMS14-PR04
Published: 13 February 2015
View article titled, Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors
Journal Articles

Combining genetic analyses and pre-clinical studies in melanoma defines multiple sub-populations with differential responses to targeted therapies

Keiran Smalley, Min Xiao, Maurizia Dalla Palma, Mercedes Lioni, Meenhard Herlyn, Keith Flaherty, Katherine Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15_Supplement): A30.
Published: 15 August 2014
View article titled, Combining genetic analyses and pre-clinical studies in melanoma defines multiple sub-populations with differential responses to targeted therapies
Journal Articles

Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth

Zhenyu Ji, Raj Kumar, Michael Taylor, Anpuchchelvi Rajadurai, Alexander Marzuka-Alcalá, Y. Erin Chen, Ching-Ni Jenny Njauw, Keith Flaherty, Göran Jönsson, Hensin Tsao
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (16): 4383–4391.
https://doi.org/10.1158/1078-0432.CCR-13-0074
Published: 13 August 2013
View article titled, Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth
Open the PDF for Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth in another window
Includes: Supplementary data